Barbara Bohn1, Wolfgang Kerner2, Jochen Seufert3, Hans-Peter Kempe4, Peter M Jehle5, Frank Best6, Martin Füchtenbusch7, Andreas Knauerhase8, Martin Hofer9, Joachim Rosenbauer10, Reinhard W Holl11. 1. University of Ulm, Institute of Epidemiology and Medical Biometry, ZIBMT, Ulm, Germany; German Center for Diabetes Research (DZD) , München-Neuherberg, Germany. Electronic address: barbara.bohn@uni-ulm.de. 2. Centre of Diabetes and Metabolic Disorders, Karlsburg, Germany. 3. University Hospital of Freiburg, Division of Endocrinology & Diabetology, Department of Medicine II, Freiburg, Germany. 4. Centre for Diabetes and Nutrition Ludwigshafen, Ludwigshafen, Germany. 5. Academic Hospital Paul Gerhardt Stift, Lutherstadt Wittenberg, Department of Internal Medicine I, Martin-Luther-University Halle-Wittenberg, Germany. 6. Diabetes-Practice Dr. Best, Essen, Germany. 7. Diabetes Practice, Munich, Germany. 8. University Hospital of Rostock, Clinic for Internal Medicine, Department of Endocrinology and Metabolic Diseases, Rostock, Germany. 9. University Hospital St. Poelten, Karl Landsteiner University of Health Sciences, Department of Internal Medicine I, St. Poelten, Austria. 10. Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Center at University of Düsseldorf, Düsseldorf, Germany; German Center for Diabetes Research (DZD) , München-Neuherberg, Germany. 11. University of Ulm, Institute of Epidemiology and Medical Biometry, ZIBMT, Ulm, Germany; German Center for Diabetes Research (DZD) , München-Neuherberg, Germany.
Abstract
AIMS: To analyse time trends of antihyperglycaemic therapy and glycaemic control in adult subjects with type 1, or type 2 diabetes between 2002 and 2014 in Germany/Austria. METHODS: 184,864 adults with diabetes (35,144 type 1 diabetes (T1D), 149,720 type 2 diabetes (T2D)) from the DPV-database documented between 2002 and 2014 were included. Regression models were applied for antihyperglycaemic therapy in T2D (non-pharmacological, OADs only, insulin±OADs), insulin therapy in T1D (CT, ICT, CSII) and T2D (BOT, SIT, CT, ICT, CSII), for the use of insulin analogues, and for glycaemic control (HbA1C, severe hypoglycaemia), adjusting for confounders sex, age, and diabetes duration. RESULTS: In T1D, CT (2002:19.7%; 2014:16.0%) and ICT (2002:66.8%; 2014:52.4%) decreased, while CSII increased from 13.5% to 31.5%. In T2D, non-pharmacological treatment became less frequent (2002:36.0%, 2014:21.8%), the use of OADs (2002:19.3%, 2014:28.9%) and insulin±OADs (2002:44.6%, 2014:49.4%) increased. BOT increased from 7.9% to 18.9%, SIT decreased from 12.0% to 8.3%. ICT slightly increased (2002:44.0%, 2014:45.3%), CT decreased (2002:35.8%, 2014:27.2%). Insulin analogues were used more frequently in T1D (rapid-acting:2002:46.8%, 2014:84.8%; long-acting:2002:26.0%, 2014:54.8%) and in T2D (rapid-acting:2002:26.0%, 2014:43.5%; long-acting:2002:13.7%, 2014:53.6%). Until 2011, HbA1C increased in T1D and T2D, but then decreased again. High variability in the rate of hypoglycaemia was observed. CONCLUSIONS: This observational study indicates an increased use of insulin pumps in T1D. In T2D, non-pharmacological therapy decreased, and insulin therapy, particular as BOT, rose. An increase in the use of rapid- and long-acting insulin analogues was present in both patient-groups. Time trend was less clear in glycaemic control.
AIMS: To analyse time trends of antihyperglycaemic therapy and glycaemic control in adult subjects with type 1, or type 2 diabetes between 2002 and 2014 in Germany/Austria. METHODS: 184,864 adults with diabetes (35,144 type 1 diabetes (T1D), 149,720 type 2 diabetes (T2D)) from the DPV-database documented between 2002 and 2014 were included. Regression models were applied for antihyperglycaemic therapy in T2D (non-pharmacological, OADs only, insulin±OADs), insulin therapy in T1D (CT, ICT, CSII) and T2D (BOT, SIT, CT, ICT, CSII), for the use of insulin analogues, and for glycaemic control (HbA1C, severe hypoglycaemia), adjusting for confounders sex, age, and diabetes duration. RESULTS: In T1D, CT (2002:19.7%; 2014:16.0%) and ICT (2002:66.8%; 2014:52.4%) decreased, while CSII increased from 13.5% to 31.5%. In T2D, non-pharmacological treatment became less frequent (2002:36.0%, 2014:21.8%), the use of OADs (2002:19.3%, 2014:28.9%) and insulin±OADs (2002:44.6%, 2014:49.4%) increased. BOT increased from 7.9% to 18.9%, SIT decreased from 12.0% to 8.3%. ICT slightly increased (2002:44.0%, 2014:45.3%), CT decreased (2002:35.8%, 2014:27.2%). Insulin analogues were used more frequently in T1D (rapid-acting:2002:46.8%, 2014:84.8%; long-acting:2002:26.0%, 2014:54.8%) and in T2D (rapid-acting:2002:26.0%, 2014:43.5%; long-acting:2002:13.7%, 2014:53.6%). Until 2011, HbA1C increased in T1D and T2D, but then decreased again. High variability in the rate of hypoglycaemia was observed. CONCLUSIONS: This observational study indicates an increased use of insulin pumps in T1D. In T2D, non-pharmacological therapy decreased, and insulin therapy, particular as BOT, rose. An increase in the use of rapid- and long-acting insulin analogues was present in both patient-groups. Time trend was less clear in glycaemic control.
Authors: Gesine van Mark; Sascha R Tittel; Reinhard Welp; Jörg Gloyer; Stefan Sziegoleit; Ralf Barion; Peter M Jehle; Dieter Erath; Peter Bramlage; Stefanie Lanzinger Journal: BMJ Open Diabetes Res Care Date: 2021-06
Authors: Bettina Hartmann; Stefanie Lanzinger; Peter Bramlage; Felix Groß; Thomas Danne; Siegfried Wagner; Dietmar Krakow; Artur Zimmermann; Christian Malcharzik; Reinhard W Holl Journal: PLoS One Date: 2017-08-21 Impact factor: 3.240
Authors: Colette Mair; Wahyu Wulaningsih; Anita Jeyam; Stuart McGurnaghan; Luke Blackbourn; Brian Kennon; Graham Leese; Robert Lindsay; Rory J McCrimmon; John McKnight; John R Petrie; Naveed Sattar; Sarah H Wild; Nicholas Conway; Ian Craigie; Kenneth Robertson; Louise Bath; Paul M McKeigue; Helen M Colhoun Journal: Diabetologia Date: 2019-05-18 Impact factor: 10.122
Authors: Valeria Manicardi; Giuseppina Russo; Angela Napoli; Elisabetta Torlone; Patrizia Li Volsi; Carlo Bruno Giorda; Nicoletta Musacchio; Antonio Nicolucci; Concetta Suraci; Giuseppe Lucisano; Maria Chiara Rossi Journal: PLoS One Date: 2016-10-03 Impact factor: 3.240
Authors: Heiner Claessen; Maria Narres; Burkhard Haastert; Werner Arend; Falk Hoffmann; Stephan Morbach; Gerhard Rümenapf; Tatjana Kvitkina; Heiko Friedel; Christian Günster; Ingrid Schubert; Walter Ullrich; Benjamin Westerhoff; Adrian Wilk; Andrea Icks Journal: Clin Epidemiol Date: 2018-04-20 Impact factor: 4.790
Authors: Gesine van Mark; Sascha R Tittel; Stefan Sziegoleit; Franz Josef Putz; Mesut Durmaz; Michaela Bortscheller; Ivo Buschmann; Jochen Seufert; Reinhard W Holl; Peter Bramlage Journal: Ther Adv Endocrinol Metab Date: 2020-09-20 Impact factor: 3.565